Zhejiang Hisoar Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Zhejiang Hisoar Pharmaceutical has a total shareholder equity of CN¥5.5B and total debt of CN¥1.1B, which brings its debt-to-equity ratio to 20.3%. Its total assets and total liabilities are CN¥7.6B and CN¥2.1B respectively.
Key information
20.3%
Debt to equity ratio
CN¥1.11b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥1.48b |
| Equity | CN¥5.46b |
| Total liabilities | CN¥2.15b |
| Total assets | CN¥7.61b |
Recent financial health updates
Is Zhejiang Hisoar Pharmaceutical (SZSE:002099) Using Debt In A Risky Way?
Jan 05
Does Zhejiang Hisoar Pharmaceutical (SZSE:002099) Have A Healthy Balance Sheet?
Aug 30Zhejiang Hisoar Pharmaceutical (SZSE:002099) Has Debt But No Earnings; Should You Worry?
May 27Recent updates
Is Zhejiang Hisoar Pharmaceutical (SZSE:002099) Using Debt In A Risky Way?
Jan 05Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Price Is Out Of Tune With Revenues
Sep 27Does Zhejiang Hisoar Pharmaceutical (SZSE:002099) Have A Healthy Balance Sheet?
Aug 30Zhejiang Hisoar Pharmaceutical (SZSE:002099) Has Debt But No Earnings; Should You Worry?
May 27Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Shares Climb 28% But Its Business Is Yet to Catch Up
Mar 03Financial Position Analysis
Short Term Liabilities: 002099's short term assets (CN¥2.8B) exceed its short term liabilities (CN¥2.1B).
Long Term Liabilities: 002099's short term assets (CN¥2.8B) exceed its long term liabilities (CN¥95.3M).
Debt to Equity History and Analysis
Debt Level: 002099 has more cash than its total debt.
Reducing Debt: 002099's debt to equity ratio has increased from 5.8% to 20.3% over the past 5 years.
Debt Coverage: 002099's debt is not well covered by operating cash flow (12%).
Interest Coverage: Insufficient data to determine if 002099's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 03:05 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Hisoar Pharmaceutical Co., Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peng Yan | Changjiang Securities Co. LTD. |
| Liang Sun | China International Capital Corporation Limited |
| Jie Yao | Everbright Securities Co. Ltd. |